

# Philip Korthuis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/266043/publications.pdf>

Version: 2024-02-01

177  
papers

8,679  
citations

57758

44  
h-index

51608

86  
g-index

178  
all docs

178  
docs citations

178  
times ranked

10845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. <i>PLoS ONE</i> , 2013, 8, e81355.	2.5	1,111
2	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. <i>Science</i> , 2010, 330, 1551-1557.	12.6	1,054
3	Cumulative Incidence of Cancer Among Persons With HIV in North America. <i>Annals of Internal Medicine</i> , 2015, 163, 507-518.	3.9	271
4	Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 96-103.	2.1	252
5	Primary Care-Based Models for the Treatment of Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2017, 166, 268.	3.9	224
6	HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S22-S32.	2.1	223
7	A Multicenter Study of Physician Mindfulness and Health Care Quality. <i>Annals of Family Medicine</i> , 2013, 11, 421-428.	1.9	186
8	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2214.	7.4	172
9	Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 249-259.	2.1	144
10	Hospital and Outpatient Health Services Utilization Among HIV-Infected Adults in Care 2000-2002. <i>Medical Care</i> , 2005, 43, III-40.	2.4	137
11	Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 2796-2803.	2.6	132
12	Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder. <i>Journal of Hospital Medicine</i> , 2017, 12, 339-342.	1.4	123
13	Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2005, 143, 55.	3.9	114
14	Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1701.	7.4	111
15	It's Been an Experience, a Life Learning Experience: A Qualitative Study of Hospitalized Patients with Substance Use Disorders. <i>Journal of General Internal Medicine</i> , 2017, 32, 296-303.	2.6	109
16	Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 1692-1702.	4.0	105
17	Comparing different measures of retention in outpatient HIV care. <i>Aids</i> , 2012, 26, 1131-1139.	2.2	101
18	Patient-Provider Communication Differs for Black Compared to White HIV-Infected Patients. <i>AIDS and Behavior</i> , 2011, 15, 805-811.	2.7	98

#	ARTICLE	IF	CITATIONS
19	Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. <i>Lancet</i> , The, 2006, 368, 1503-1515.	13.7	92
20	Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance Use. <i>AIDS Patient Care and STDs</i> , 2008, 22, 859-867.	2.5	90
21	Patient Activation and Improved Outcomes in HIV-Infected Patients. <i>Journal of General Internal Medicine</i> , 2013, 28, 668-674.	2.6	90
22	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001â€“2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	5.8	90
23	Clinician empathy is associated with differences in patientâ€“clinician communication behaviors and higher medication self-efficacy in HIV care. <i>Patient Education and Counseling</i> , 2016, 99, 220-226.	2.2	89
24	Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. <i>American Journal of Public Health</i> , 2012, 102, 1160-1167.	2.7	86
25	Alcohol use among HIVâ€“infected persons in care: results of a multiâ€“site survey<sup>*</sup>. <i>HIV Medicine</i> , 2008, 9, 196-202.	2.2	82
26	Primary Care Provider Cultural Competence and Racial Disparities in HIV Care and Outcomes. <i>Journal of General Internal Medicine</i> , 2013, 28, 622-629.	2.6	79
27	Differences in Patientâ€“Provider Communication for Hispanic Compared to Non-Hispanic White Patients in HIV Care. <i>Journal of General Internal Medicine</i> , 2010, 25, 682-687.	2.6	78
28	HIV Risk Reduction With Buprenorphineâ€“Naloxone or Methadone. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 288-293.	2.1	77
29	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014, 50, 1169-1176.	1.5	77
30	Internet Health Information Seeking Behavior and Antiretroviral Adherence in Persons Living with HIV/AIDS. <i>AIDS Patient Care and STDs</i> , 2011, 25, 445-449.	2.5	68
31	The impact of illicit drug use and substance abuse treatment on adherence to HAART. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 1134-1140.	1.2	65
32	Retention in Care Is More Strongly Associated With Viral Suppression in HIV-Infected Patients With Lower Versus Higher CD4 Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 333-339.	2.1	63
33	Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S39-S45.	2.1	60
34	The Impact of Integrated HIV Care on Patient Health Outcomes. <i>Medical Care</i> , 2009, 47, 560-567.	2.4	59
35	Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. <i>Annual Review of Public Health</i> , 2018, 39, 525-541.	17.4	57
36	Patients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care. <i>Journal of Addiction Medicine</i> , 2010, 4, 204-210.	2.6	56

#	ARTICLE	IF	CITATIONS
37	Prenatal Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2005, 143, 38.	3.9	54
38	Buprenorphine+Analogone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. <i>Addiction</i> , 2016, 111, 1416-1427.	3.3	53
39	Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. <i>Annals of Internal Medicine</i> , 2018, 169, 335-336.	3.9	53
40	Unhealthy Alcohol and Illicit Drug Use Are Associated With Decreased Quality of HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 171-178.	2.1	51
41	Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. <i>Addiction</i> , 2017, 112, 1036-1044.	3.3	51
42	Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings. <i>Annals of Internal Medicine</i> , 2017, 167, 867.	3.9	51
43	General Internists' Beliefs, Behaviors, and Perceived Barriers to Routine HIV Screening in Primary Care. <i>AIDS Education and Prevention</i> , 2011, 23, 70-83.	1.1	50
44	Impact of a brief patient and provider intervention to improve the quality of communication about medication adherence among HIV patients. <i>Patient Education and Counseling</i> , 2015, 98, 1078-1083.	2.2	49
45	Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 1-6.	3.1	48
46	The role of cultural distance between patient and provider in explaining racial/ethnic disparities in HIV care. <i>Patient Education and Counseling</i> , 2011, 85, e278-e284.	2.2	47
47	Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S83-S90.	2.1	45
48	Structures of Care in the Clinics of the HIV Research Network. <i>AIDS Patient Care and STDs</i> , 2008, 22, 1007-1013.	2.5	43
49	Race, Relationships, and Trust in Providers among Black Patients with HIV/AIDS. <i>Social Work Research</i> , 2013, 37, 219-226.	0.6	43
50	Providing support to patients in emotional encounters: A new perspective on missed empathic opportunities. <i>Patient Education and Counseling</i> , 2012, 88, 436-442.	2.2	42
51	The Source of Methadone in Overdose Deaths in Western Virginia in 2004. <i>Journal of Addiction Medicine</i> , 2011, 5, 188-202.	2.6	41
52	Provider-patient Adherence Dialogue in HIV Care: Results of a Multisite Study. <i>AIDS and Behavior</i> , 2013, 17, 148-159.	2.7	40
53	Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018. <i>PLoS ONE</i> , 2020, 15, e0242165.	2.5	40
54	Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service. <i>Journal of Addiction Medicine</i> , 2020, 14, 415-422.	2.6	39

#	ARTICLE	IF	CITATIONS
55	A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews. <i>Journal of General Internal Medicine</i> , 2022, 37, 2821-2833.	2.6	39
56	Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions. <i>Journal of Substance Abuse Treatment</i> , 2008, 35, 294-303.	2.8	37
57	Integrase strand transfer inhibitor-associated diabetes mellitus: A case report. <i>International Journal of STD and AIDS</i> , 2017, 28, 626-628.	1.1	37
58	Substance Use and the Quality of Patient-Provider Communication in HIV Clinics. <i>AIDS and Behavior</i> , 2011, 15, 832-841.	2.7	36
59	A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108193.	3.2	36
60	Emergency department utilization among HIV-infected patients in a multisite multistate study. <i>HIV Medicine</i> , 2010, 11, 74-84.	2.2	35
61	“Like Yin and Yang” Perceptions of Methamphetamine Benefits and Consequences Among People Who Use Opioids in Rural Communities. <i>Journal of Addiction Medicine</i> , 2021, 15, 34-39.	2.6	35
62	A mixed methods study of patient-provider communication about opioid analgesics. <i>Patient Education and Counseling</i> , 2015, 98, 453-461.	2.2	33
63	Respecting patients is associated with more patient-centered communication behaviors in clinical encounters. <i>Patient Education and Counseling</i> , 2016, 99, 250-255.	2.2	33
64	Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. <i>Pain</i> , 2022, 163, 83-90.	4.2	33
65	Screening for HIV: Systematic Review to Update the 2005 U.S. Preventive Services Task Force Recommendation. <i>Annals of Internal Medicine</i> , 2012, 157, 706.	3.9	32
66	Pregnancy Incidence and Outcomes in Vertically and Behaviorally HIV-Infected Youth. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 468.	7.4	31
67	Decision-Making Role Preferences Among Patients with HIV: Associations with Patient and Provider Characteristics and Communication Behaviors. <i>Journal of General Internal Medicine</i> , 2010, 25, 517-523.	2.6	30
68	Disparities in Antiretroviral Treatment: A Comparison of Behaviorally HIV-Infected Youth and Adults in the HIV Research Network. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 100-107.	2.1	29
69	Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. <i>Drug and Alcohol Dependence</i> , 2019, 198, 70-75.	3.2	29
70	Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: A latent transition analysis. <i>Journal of Substance Abuse Treatment</i> , 2020, 118, 108121.	2.8	28
71	Thirty-day hospital readmission rate among adults living with HIV. <i>Aids</i> , 2013, 27, 2059-2068.	2.2	27
72	Factors associated with willingness to take extended release naltrexone among injection drug users. <i>Addiction Science &amp; Clinical Practice</i> , 2015, 10, 12.	2.6	27

#	ARTICLE	IF	CITATIONS
73	Substance use and the HIV care continuum: important advances. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 13.	2.6	27
74	Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review. <i>Journal of Addiction Medicine</i> , 2021, 15, 74-84.	2.6	27
75	Predictors of Highly Active Antiretroviral Therapy Utilization for Behaviorally HIV-1-Infected Youth: Impact of Adult Versus Pediatric Clinical Care Site. <i>Journal of Adolescent Health</i> , 2012, 50, 471-477.	2.5	26
76	Does This Adult Patient Have Early HIV Infection?. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 278.	7.4	26
77	Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 607.	7.4	26
78	Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. <i>BMC Health Services Research</i> , 2019, 19, 862.	2.2	26
79	Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 72.	2.6	26
80	Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 141, 108801.	2.8	26
81	Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. <i>Current HIV/AIDS Reports</i> , 2018, 15, 315-323.	3.1	25
82	Changes in Advanced Immunosuppression and Detectable HIV Viremia Among Perinatally HIV-Infected Youth in the Multisite United States HIV Research Network. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 215-223.	1.3	24
83	Measuring Medication. <i>Medical Care</i> , 2002, 40, 1270-1282.	2.4	23
84	Lessons Learned from the Implementation of a Medically Enhanced Residential Treatment (MERT) Model Integrating Intravenous Antibiotics and Residential Addiction Treatment. <i>Substance Abuse</i> , 2018, 39, 225-232.	2.3	23
85	COVID-19-Related Policy Changes for Methadone Take-Home Dosing: A Multistate Survey of Opioid Treatment Program Leadership. <i>Substance Abuse</i> , 2022, 43, 633-639.	2.3	23
86	Provider-Patient Communication About Adherence to Anti-retroviral Regimens Differs by Patient Race and Ethnicity. <i>AIDS and Behavior</i> , 2014, 18, 1279-1287.	2.7	22
87	Quality of HIV Care and Mortality Rates in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2016, 62, 233-239.	5.8	22
88	A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 192, 186-192.	3.2	22
89	Harm Reduction and Adaptations Among PWUD in Rural Oregon During COVID-19. <i>AIDS and Behavior</i> , 2021, 25, 1331-1339.	2.7	21
90	Healthcare Coverage for HIV Provider Visits Before and After Implementation of the Affordable Care Act. <i>Clinical Infectious Diseases</i> , 2016, 63, 387-395.	5.8	20

#	ARTICLE	IF	CITATIONS
91	Patient and provider comfort discussing substance use. <i>Family Medicine</i> , 2013, 45, 109-17.	0.5	20
92	Associations between Outpatient and Inpatient Service Use among Persons with HIV Infection: A Positive or Negative Relationship?. <i>Health Services Research</i> , 2007, 43, 76-95.	2.0	19
93	Use of outpatient mental health services and psychotropic medications among HIV-infected patients in a multisite, multistate study. <i>General Hospital Psychiatry</i> , 2009, 31, 538-545.	2.4	19
94	Factors Affecting Clinician Educator Encouragement of Routine HIV Testing Among Trainees. <i>Journal of General Internal Medicine</i> , 2012, 27, 839-844.	2.6	19
95	Racial disparities in clinician responses to patient emotions. <i>Patient Education and Counseling</i> , 2020, 103, 1736-1744.	2.2	19
96	The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S76-S82.	2.1	18
97	Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004â€“2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 409-416.	2.1	18
98	Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. <i>Lancet HIV</i> , 2019, 6, e531-e539.	4.7	18
99	Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness. <i>Addictive Behaviors</i> , 2012, 37, 552-555.	3.0	17
100	Counseling to Reduce High-Risk Sexual Behavior in HIV Care: A Multi-Center, Direct Observation Study. <i>AIDS Patient Care and STDs</i> , 2013, 27, 416-424.	2.5	17
101	Correlates of HIV Risk Behaviors among Homeless and Unstably Housed Young Adults. <i>Public Health Reports</i> , 2013, 128, 153-160.	2.5	17
102	Trends in Hospitalizations Among Children and Young Adults with Perinatally Acquired HIV. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 488-494.	2.0	17
103	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 275-279.	2.1	17
104	HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2021, 8, e67-e76.	4.7	17
105	Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. <i>Drug and Alcohol Dependence</i> , 2021, 228, 108923.	3.2	17
106	The impact of depressive symptoms on patientâ€™provider communication in HIV care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 1185-1192.	1.2	16
107	Hepatitis C Virus Testing in Adults Living with HIV: A Need for Improved Screening Efforts. <i>PLoS ONE</i> , 2014, 9, e102766.	2.5	16
108	Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. <i>Journal of Substance Abuse Treatment</i> , 2019, 103, 23-32.	2.8	16

#	ARTICLE	IF	CITATIONS
109	Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. <i>Journal of Substance Abuse Treatment</i> , 2020, 109, 14-22.	2.8	16
110	“We” Do this Together: The Role of the First Person Plural in Fostering Partnership in Patient-physician Relationships. <i>Journal of General Internal Medicine</i> , 2010, 25, 186-193.	2.6	15
111	Motivational interviewing by HIV care providers is associated with patient intentions to reduce unsafe sexual behavior. <i>Patient Education and Counseling</i> , 2013, 93, 122-129.	2.2	15
112	HIV Patients' Preference for Integrated Models of Addiction and HIV Treatment in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2016, 69, 57-63.	2.8	15
113	Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. <i>Health and Justice</i> , 2020, 8, 18.	2.1	15
114	Impact of Patient Race on Patient Experiences of Access and Communication in HIV Care. <i>Journal of General Internal Medicine</i> , 2008, 23, 2046-2052.	2.6	14
115	Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000–2005. <i>Aids</i> , 2011, 25, 717-720.	2.2	14
116	HIV Providers' Perceptions of and Attitudes Toward Female Versus Male Patients. <i>AIDS Patient Care and STDs</i> , 2012, 26, 582-588.	2.5	14
117	Clinician Stress and Patient–Clinician Communication in HIV Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 1635-1642.	2.6	13
118	Conformity of Pediatric/Adolescent HIV Clinics to the Patient-Centered Medical Home Care Model. <i>AIDS Patient Care and STDs</i> , 2013, 27, 272-279.	2.5	13
119	Effects of Naltrexone on Large-Scale Network Interactions in Methamphetamine Use Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 603.	2.6	13
120	Causes of Death in the 12 Months After Hospital Discharge Among Patients With Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2022, 16, 466-469.	2.6	13
121	Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. <i>American Journal of Managed Care</i> , 2011, 17 Suppl 8, S222-34.	1.1	13
122	The SUMMIT ambulatory-ICU primary care model for medically and socially complex patients in an urban federally qualified health center: study design and rationale. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 27.	2.6	12
123	Use of single IRBs for multi-site studies: A case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. <i>Contemporary Clinical Trials Communications</i> , 2019, 14, 100319.	1.1	12
124	Racial/ethnic differences in the association between alcohol use and mortality among men living with HIV. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 2.	2.6	11
125	Emotional Communication in HIV Care: An Observational Study of Patients' Expressed Emotions and Clinician Response. <i>AIDS and Behavior</i> , 2019, 23, 2816-2828.	2.7	11
126	Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 3188-3196.	2.6	11



#	ARTICLE	IF	CITATIONS
127	Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study. Drug and Alcohol Dependence, 2021, 227, 108912.	3.2	11
128	Lipid Screening in HIV-Infected Veterans. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 253-260.	2.1	10
129	HIV rapid testing in drug treatment: comparison across treatment modalities. Journal of Substance Abuse Treatment, 2013, 44, 369-374.	2.8	10
130	Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients?. AIDS and Behavior, 2016, 20, 1108-1115.	2.7	10
131	Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. Drug and Alcohol Dependence, 2021, 228, 109077.	3.2	10
132	Addressing Missing Data in Substance Use Research: A Review and Data Justice-based Approach. Journal of Addiction Medicine, 2020, 14, 454-456.	2.6	10
133	HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. Addiction, 2022, 117, 1961-1971.	3.3	10
134	Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001-2009. PLoS ONE, 2013, 8, e78952.	2.5	9
135	Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the <sc>HIV</sc> Research Network. HIV Medicine, 2019, 20, 169-174.	2.2	9
136	HIV care continuum characteristics among people with opioid use disorder and HIV in Vietnam: baseline results from the BRAVO study. BMC Public Health, 2020, 20, 421.	2.9	8
137	Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug and Alcohol Dependence, 2020, 217, 108272.	3.2	8
138	Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS and Behavior, 2022, 26, 975-985.	2.7	8
139	Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures?. Journal of General Internal Medicine, 2016, 31, 1141-1147.	2.6	7
140	Designing and validating a Markov model for hospital-based addiction consult service impact on 12-month drug and non-drug related mortality. PLoS ONE, 2021, 16, e0256793.	2.5	7
141	"It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply. Harm Reduction Journal, 2022, 19, .	3.2	7
142	Provider and Practice Characteristics Associated with Use of Rapid HIV Testing by General Internists. Journal of General Internal Medicine, 2011, 26, 1258-64.	2.6	6
143	A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations. Addictive Behaviors, 2018, 86, 32-39.	3.0	6
144	Are clinicians' self-reported empathic concern and perspective-taking traits associated with their response to patient emotions?. Patient Education and Counseling, 2020, 103, 1745-1751.	2.2	6

#	ARTICLE	IF	CITATIONS
145	“Sobriety equals getting rid of hepatitis C” A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. <i>Journal of Substance Abuse Treatment</i> , 2021, 127, 108337.	2.8	6
146	Implementation of a cross-cultural evidence-based medicine curriculum. <i>Medical Teacher</i> , 2002, 24, 444-446.	1.8	5
147	NIDA’s Clinical Trials Network: An Opportunity for HIV Research in Community Substance Abuse Treatment Programs. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 283-293.	2.1	5
148	Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 395-399.	1.9	5
149	Provider Perspectives on Integration of Substance Use Disorder and HIV Care in Vietnam: A Qualitative Study. <i>Journal of Behavioral Health Services and Research</i> , 2021, 48, 274-286.	1.4	5
150	Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2022, 134, 108451.	2.8	5
151	Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108615.	2.8	5
152	A cross-sectional survey of potential factors, motivations, and barriers influencing research participation and retention among people who use drugs in the rural USA. <i>Trials</i> , 2021, 22, 948.	1.6	5
153	A Delayed Injection-Site Reaction in a Patient Receiving Extended-Release Naltrexone. <i>Substance Abuse</i> , 2016, 37, 278-280.	2.3	4
154	How does decision complexity affect shared decision making? An analysis of patient-provider antiretroviral initiation dialogue. <i>Patient Education and Counseling</i> , 2017, 100, 919-926.	2.2	4
155	Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study. <i>BMC Public Health</i> , 2021, 21, 1718.	2.9	4
156	The process and challenges of language translation and cultural adaptation of study instruments: a case study from the NIDA CTN CHOICES-2 trial. <i>Journal of Ethnicity in Substance Abuse</i> , 2023, 22, 417-432.	0.9	3
157	Three integrated elements of empowerment: HIV prevention with sub-Saharan African adolescent females involved in transactional sex.. <i>Clinical Practice in Pediatric Psychology</i> , 2018, 6, 355-363.	0.3	3
158	Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation. <i>Journal of Addiction Medicine</i> , 2021, 15, 130-133.	2.6	3
159	Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality. <i>International Journal of Drug Policy</i> , 2022, 100, 103525.	3.3	3
160	Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 67.	2.6	3
161	COVID-19 Vaccination Status and Concerns Among People Who Use Drugs in Oregon. <i>Journal of Addiction Medicine</i> , 2022, 16, 695-701.	2.6	3
162	Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. <i>Annals of Internal Medicine</i> , 2019, 170, 509.	3.9	2

#	ARTICLE	IF	CITATIONS
163	Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. <i>International Journal of Drug Policy</i> , 2021, 96, 103356.	3.3	2
164	Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study. <i>Journal of Behavioral Health Services and Research</i> , 2022, 49, 240-251.	1.4	2
165	Familial Support in Integrated Treatment with Antiretroviral Therapy and Medications for Opioid use Disorder in Vietnam: A Qualitative Study. <i>Substance Abuse</i> , 2022, 43, 1004-1010.	2.3	2
166	Contraception and Healthcare Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities: a Cross-Sectional Survey. <i>Journal of General Internal Medicine</i> , 2023, 38, 98-106.	2.6	2
167	Exploring how Hospitalization Can Alter Hepatitis C Virus Treatment Prioritization and Trajectories in People who Use Drugs: A Qualitative Analysis. <i>Substance Abuse</i> , 2022, 43, 245-252.	2.3	1
168	Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108509.	2.8	1
169	Authors' Reply. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e142-e143.	2.1	0
170	Drug and Alcohol Dependence response to KK-21-1460 "Considering rationales for use in defining subgroups for the treatment of stimulant use disorder". <i>Drug and Alcohol Dependence</i> , 2021, 221, 108571.	3.2	0
171	Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam. <i>International Journal of Drug Policy</i> , 2022, 100, 103503.	3.3	0
172	Evaluation of a Medicaid performance improvement project to reduce high-dose opioid prescriptions. <i>BMC Health Services Research</i> , 2022, 22, 68.	2.2	0
173	Title is missing!. , 2020, 15, e0242165.		0
174	Title is missing!. , 2020, 15, e0242165.		0
175	Title is missing!. , 2020, 15, e0242165.		0
176	Title is missing!. , 2020, 15, e0242165.		0
177	Stigma as a barrier to integrated substance use and HIV care in Vietnam: A qualitative examination of patient and provider perspectives. <i>Journal of Ethnicity in Substance Abuse</i> , 2024, 23, 182-197.	0.9	0